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Abstract Bisdioxopiperazine anti-cancer agents are catalytic
inhibitors of topoisomerase II which by unknown means lock the
enzyme in a closed clamp form and inhibit its ATPase activity. In
order to demarcate a putative pharmacophore, we here describe a
novel Tyr165Ser mutation in the enzyme’s Walker A ATP
binding site leading to specific bisdioxopiperazine resistance
when transformed into a temperature-conditional yeast system.
The Tyr165Ser mutation differed from a previously described
Arg162Gln by being heterozygous and by purified Tyr165Ser
enzyme being drug-resistant in a kinetoplast DNA decatenation
enzymatic assay. This suggested dominant nature of Tyr165Ser
was supported by co-transformation studies in yeast of plasmids
carrying wild type and mutant genes. These results enable a
model of the bisdioxopiperazine pharmacophore using the
proposed asymmetric ATP hydrolysis of the enzyme. + 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
DNA topoisomerase II is an essential nuclear enzyme that
catalyzes the ATP-dependent transport of one DNA double
helix through a transient double strand break in a second
helix [1,2]. It is required in many aspects of DNA metabolism
such as transcription, replication and recombination, as well
as being essential for chromosome segregation during mitosis.
The mammalian type II enzyme exists as two isozymes, a 180
kDa L enzyme expressed evenly throughout the cell cycle, and
a 170 kDa K enzyme that is primarily expressed in the G2/M
phase.
Topoisomerase II is one of the most important cellular
targets for clinically used anti-cancer drugs [3]. These drugs
are divided into two groups according to where they act on
the catalytic cycle, namely poisons and catalytic inhibitors.
Drugs such as the anthracyclines, the epipodophyllotoxins
as well as the aminoacridines all act at the stage in the cata-
lytic cycle where the gate DNA strand is cleaved, stabilizing
an enzyme^DNA cleavable complex that leads to irreversible
DNA breaks and cell death. These drugs are consequently
termed poisons since they convert the essential enzyme into
one which damages the cell [4]. Drugs that act on the topo-
isomerase II catalytic cycle without stabilizing cleavable
complexes are termed catalytic inhibitors. The major distinc-
tion between poisons and catalytic inhibitors is therefore that
the latter do not create DNA breaks at relevant cytotoxic
concentrations. In 1991, Ishida et al. [5] described how the
bisdioxopiperazine class of anti-cancer agents inhibited the
catalytic cycle of topoisomerase II without creating DNA
breaks. Subsequent papers from di¡erent groups have demon-
strated that the bisdioxopiperazines appear to have two highly
speci¢c and distinct e¡ects on topoisomerase II, namely lock-
ing its N-terminal clamp and inhibiting its ATPase activity [6^
8]. The mechanism of action of the bisdioxopiperazine ICRF-
193 on yeast topoisomerase II was recently extensively studied
by Morris et al. [9] who reported that the drug interacts with
the enzyme with one monomer bound to ADP. However, it is
still unknown how these drugs molecularly interact with the
enzyme. One way of demarcating a possible pharmacophore is
to study mutations which confer drug resistance. We and
others have previously found such mutations in mammalian
cell lines which are clustered in the N-terminal clamp in two
sites, namely at Thr49Ile [10] and Tyr50Phe [11], and at
Arg162Gln [12] in the Walker A ATP binding motif of aa
161GXXGXG166 [13]. In addition, using random mutagenesis
and selection in yeast, two groups independently discovered a
Leu169Phe mutation which is just next to this Walker A motif
[14,15]. In the present study we describe a novel Tyr165Ser
mutation that was detected in human small cell lung cancer
cells which di¡ers from the neighboring Arg162Gln in several
respects. Using the asymmetric ATP hydrolysis of topoiso-
merase II blocked by ICRF-193 proposed in [9], this enables
a model of the putative bisdioxopiperazine pharmacophore to
be put forward.
2. Materials and methods
2.1. Drugs
The bisdioxopiperazine ICRF-187 (dexrazoxane, Cardioxane0) was
commercially obtained from Chiron (Amsterdam, The Netherlands),
vincristine from Lilly, (Copenhagen, Denmark), aclarubicin from
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Lundbeck (Copenhagen, Denmark), etoposide and cisplatin from
Bristol-Myers Squibb (Lyngby, Denmark) and camptothecin from
Sigma (Kansas City, MO, USA). Merbarone was a generous gift
from the Drug Synthesis and Chemistry Branch, Developmental Ther-
apeutics Program, Division of Cancer Treatment, NCI, NIH, Bethes-
da, MD, USA.
2.2. Cells and clonogenic assay
Human small cell lung cancer NYH cells were selected through
approximately 20 passages in increasing concentrations of ICRF-187
until they were resistant to 1 mM drug. A 3 week clonogenic assay
using soft agar on a sheep red blood cell feeder layer was used with
continuous drug incubation.
2.3. Alkaline elution assay
The alkaline elution assay for measuring DNA single strand breaks
in intact NYH cells was performed as described in [11].
2.4. Western blot and band depletion assays
Western blots were performed as previously described in [12] using
either a monoclonal antibody for the K (Cambridge Research Bio-
chemicals, Cheshire, UK) or a polyclonal antibody for the L isoform
(Bio-Trend, Cologne, Germany). Band depletion assays are Western
blots performed on nuclear extracts following drug incubation of
viable cells for 1 h [12].
2.5. Sequencing of topoisomerase IIK
RT-PCR and PCR were performed as previously described [16].
Sequencing of the PCR products was performed using the ABI Prism
Dye Terminator Cycle Sequencing kit (Perkin Elmer) from both 5P
and 3P ends for two or three times each on two di¡erent mRNA
extractions using the primers previously described in [16].
2.6. Long PCR and restriction cleavage
In order to determine the expression of wild type (wt) and mutant
alleles, a full-length PCR was performed with the TaqPlus Long PCR
System (Stratagene, Amsterdam, The Netherlands) using the primers:
Topstart2: 5P-CCT GTT TAG TCG CTT TCA GGG TTC TTG
AGC-3P (348 to 319) and Stop2: 5P-GGA AGT TAA GAG CTT
CAG GTA AC-3P (4675^4653). The Tyr165Ser mutation creates an
additional restriction site for BpmI (New England Biolabs, Frankfurt
am Main, Germany) leading to two restriction sites in its gene, while
the wt only has one.
2.7. Functional characterization of mutant human topoisomerase IIK in
yeast
To assess whether the Tyr165Ser mutation found in NYH/187/165
topoisomerase IIK contributes to the acquired bisdioxopiperazine re-
sistance, the corresponding point mutation was introduced into the
episomal expression vector for human topoisomerase IIK pMJ1 by
oligonucleotide-directed mutagenesis as previously described [12] us-
ing the two mutagenic primers Tyr165Ser-SN: GGT CGA AAT GGC
TCT GGA GCC AAA TTG TG and Tyr165Ser-ASN: CAC AAT
TTG GCT CCA GAG CCA TTT CGA CC. In addition, the
Arg450Gln mutation which has been reported to confer resistance
to topoisomerase II poisons was also introduced using the primers
described in [17].
2.8. Puri¢cation and testing of wt and mutant human topoisomerase IIK
Human topoisomerase IIK was expressed for puri¢cation using the
plasmid YEpWOB6 [18] in the protease-de¢cient yeast strain Jelv
TOP1 (trp1, leu2, ura-52, pbr1-1122, pep4-3, vhis3: :PGAL10-GAL4,
TOP1: :LEU2). Induction of topoisomerase II by galactose and pro-
tein puri¢cation were as described in [12].
2.8.1. Decatenation assay. Topoisomerase II catalytic activity was
measured by kinetoplast DNA (kDNA) decatenation using 3H-labeled
kDNA isolated from Crithidia fasciculata (ATCC, Rockville, MD,
USA) as described in [12]. Brie£y, puri¢ed wt or Y165S mutant top-
oisomerase IIK was incubated with 0.2 Wg kDNA for 15 min at 37‡C
in a ¢nal volume of 20 Wl in a bu¡er containing 50 mM Tris^HCl,
pH 8, 120 mM KCl, 10 mM MgCl2, 1.0 mM ATP, 0.5 mM dithio-
threitol, 30 Wg bovine serum albumin per milliliter). After addition of
stop bu¡er/loading dye mix (5% sarcosyl, 0.0025% bromophenol blue,
25% glycerol), samples were loaded on 1% agarose/0.5% ethidium
bromide gels and run in TBE bu¡er containing 0.5 Wg/ml ethidium
bromide at 100 V for approximately 50 min. Loading wells were cut
out and scintillation counted. Thus, full activity of the enzyme entails
no remaining kDNA in the well leading to a cpm of around 0, while
inhibition of the enzyme by drug leads to increasing cpm values (see
Fig. 3).
2.8.2. DNA cleavage assay. Determination of covalent complexes
between puri¢ed wt or mutated topoisomerase II and radiolabelled
DNA induced in vitro by a drug was as described in [19].
2.9. Coexpression experiments
The constructs pMJ1 and pKN9 are both single copy episomal
ARS/CEN-based yeast expression vectors for human topoisomerase
IIK which express the protein from the constitutive and cell cycle-
independent yeast topoisomerase I promoter. pMJ1 is based on
yCP50 and carries a URA3 selectable marker while pKN9 is based
on pLAC111 and carries a LEU2 yeast selectable marker. These con-
structs have been described in detail elsewhere [17,19]. In order to
compare the dominance of the identi¢ed Tyr165Ser mutation with
the previously described Tyr50Phe mutation, co-expression experi-
ments were performed using the drug-permeable yeast strain
JN362At2-4 (MATa, ura5-2, leu2, trp1, his7, ade1-2, ISE2, leu2,
top2-4) which carries a temperature-sensitive chromosomal t2-4 topo-
isomerase II allele which is inactive at 34‡C. The following co-trans-
formations were performed: (i) pMJ1-WT (URA3)+pLAC111
(LEU2), (ii) pMJ1-Tyr50Phe (URA3)+pLAC111 (LEU2), (iii)
pMJ1-Tyr165Ser (URA3)+pLAC111 (LEU2), (iv) pMJ1-WT (UR-
A3)+pKN9 (LEU2), (v) pMJ1-Tyr50Phe (URA3)+pKN9 (LEU2),
(vi) pMJ1-Tyr165Ser (URA3)+pKN9 (LEU2). Propagation of trans-
formed cells was carried out on SC-LEU-URA medium to ensure
selection for both plasmids as described in [19]. Clonogenic assays
to determine cytotoxicity involving yeast cells containing pLAC111
(topoisomerase IIK expressed alone) were repeated two or three times,
while assays involving cells containing pKN9 (co-expression of topo-
isomerase IIK) were repeated three to ¢ve times.
3. Results
3.1. Cells and drug resistance
Three subcultures of NYH cells developed resistance to
ICRF-187 while maintaining unaltered morphology and dou-
bling times. Sequencing of the entire topoisomerase IIK
cDNA from these three sublines showed a homozygous
GCA point mutation at nt 485 as previously described [12]
in one case (designated NYH/187/162), while the other two
sublines revealed identical heterozygous ACC point muta-
tions at nt 494 causing a Tyr165Ser conversion which is also
in the Walker A motif (designated NYH/187/165). As shown
in Table 1, NYH/187/165 cells are highly resistant to the se-
lecting drug, ICRF-187, while demonstrating only minor
changes in sensitivity to other drug classes. To assess whether
the newly found Tyr165Ser mutation confers bisdioxopipera-
zine resistance, the corresponding point mutation was intro-
duced into the episomal expression vector for human topo-
isomerase IIK pMJ1 by oligonucleotide-directed mutagenesis.
Clonogenic assay in yeast revealed a highly speci¢c resistance
to both ICRF-187 and ICRF-193, but no cross-resistance to
either of the topoisomerase II poisons etoposide or m-AMSA
(Fig. 1). The Arg450Gln mutation in the Walker B consensus
site of human topoisomerase IIK has been reported to confer
resistance to topoisomerase II poisons [17]. Further, in its
puri¢ed form it has been shown to exhibit impaired ATP
utilization [20] as is also seen in the Arg162Gln [12] and the
Tyr165Ser (see below) mutants. We were therefore interested
to see whether the Arg450Gln conferred resistance to bisdioxo-
piperazines. As shown in Fig. 2, there is no cross-resistance
to ICRF-187 in yeast cells transformed with human
Arg450Gln topoisomerase IIK. This indicates that it is not
the increase in ATP requirement that is responsible for resis-
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tance to the bisdioxopiperazines in the Arg162Gln and
Tyr165Ser mutants.
3.2. Similarities and di¡erences between Arg162Gln and
Tyr165Ser
As both Arg162 and Tyr165 are in the Walker A ATP
binding site, we have compared the di¡erential phenotypes
of these mutations to obtain a better understanding of the
putative pharmacophore. A summary is also supplied in Table
2.
3.3. Similarities
In addition to the speci¢city of the bisdioxopiperazine re-
sistance described above, the following assays showed a sim-
ilar result in NYH/187/162 and/165 cells: protection of etopo-
side-induced toxicity by ICRF-187 was reduced by
approximately 50% in NYH/187/165 cells in a clonogenic as-
say, and inhibition of etoposide-induced DNA single strand
breaks by ICRF-187 measured by the standard alkaline elu-
tion technique was abolished in NYH/187/165 cells (not
shown). These results are similar to those reported for
NYH/187/162 cells [12]. Further, using Western blotting the
topoisomerase IIK and L levels were equal in NYH and NYH/
Table 1
Sensitivity of various anti-cancer drug classes in NYH and NYH/
187/165 cells
Drug (WM) NYH NYH/187/165 RR
Camptothecin 0.0015 (0.001) 0.0027 (0.000) 1.8
Etoposide 0.0407 (0.001) 0.1363 (0.001) 3.4
Amsacrine 0.027 (0.000) 0.0529 (0.003) 2
Cisplatin 0.3363 (0.176) 0.3163 (0.225) 0.9
Merbarone 4.6603 (0.806) 4.6013 (1.066) 1
Aclarubicin 0.0021 (0.001) 0.0025 (0001) 1.2
Vincristine 0.0013 (0.000) 0.0013 (0.000) 1
ICRF-187 17.885 (3.019) r r
High level resistance is only observed to the selecting agent. S.D.s
of three determinations are in parentheses. RR= relative resistance.
Fig. 1. Clonogenic assay in yeast cells transformed with either wt or
Tyr165Ser human topoisomerase IIK and incubated in increasing
concentration of drugs as indicated. Yeast cells with Tyr165Ser to-
poisomerase IIK are highly resistant to both ICRF-187 and -193
(upper panels), but show comparable sensitivity to the typical topo-
isomerase II poisons, m-AMSA and etoposide (lower panels).
Fig. 2. Clonogenic assay in yeast cells transformed with either wt or
Arg450Gln human topoisomerase IIK and incubated in increasing
concentration of drugs as indicated. Yeast cells with Arg450Gln
topoisomerase IIK exhibit the expected resistance to both etoposide
(top panel) and m-AMSA (middle panel), but have the same sensi-
tivity to ICRF-187 (lower panel).
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187/165 cells. Following 1 h incubation with ICRF-187, a
decrease in topoisomerase IIL was observed in extracts from
both NYH and NYH/187/165 cells, while the K isoform was
only depleted in NYH cells and thus unchanged in NYH/187/
165 cells indicating a speci¢city for the K isoform (not shown).
The results using Western blotting are thus the same as in
NYH/187/162 cells [12]. Though bisdioxopiperazines do not
exert their cytotoxicity by cleavable complex formation, they
are able to create a small number of DNA breaks at very high
concentrations [19]. Utilizing a conventional DNA cleavage
assay, ICRF-187-induced cleavable complexes were com-
pletely lacking in both Arg162Gln and Tyr165Ser enzymes,
while wt enzyme did produce low level cleavage (not shown).
Finally, the ATP concentration needed for 50% catalytic ac-
tivity in the kDNA decatenation assay was V30 WM for
puri¢ed wt enzyme while it was V140 WM for puri¢ed
Tyr165Ser enzyme (not shown). This increase in ATP demand
in the Tyr165Ser enzyme is similar to that reported for
Arg162Gln [12].
3.4. Di¡erences
The two distinct di¡erences between the Arg162Gln and the
Tyr165Ser mutations lie in the ability of ICRF-187 to inhibit
the catalytic activity of the enzyme using the decatenation
assay and in the suggested dominant nature of the Tyr165Ser
mutation. In the catalytic kDNA decatenation assay, puri¢ed
Tyr165Ser topoisomerase IIK was completely resistant to
ICRF-187 while Arg162Gln was sensitive (Fig. 3). This in-
creased phenotype of Tyr165Ser was also observed while se-
quencing the cDNA as NYH/187/162 cells showed a homozy-
gous GCA point mutation at nt 485, while NYH/187/165 had
a heterozygous ACC point mutation at nt 494. This hetero-
zygosity was con¢rmed using the restriction enzyme BpmI
which cuts only once in the full-length wt gene, while the nt
494 ACC mutation itself introduces an additional restriction
site enabling both transcripts to be evaluated. Utilizing BpmI
on a long topoisomerase IIK PCR from NYH/187/165 re-
vealed a cDNA with equally represented 494A and 494C tran-
scripts demonstrating that both alleles are actively transcribed
(Fig. 4). In order to explore the possibility of the Tyr165Ser
mutation being dominant, we co-expressed either Tyr50Phe or
Tyr165Ser human topoisomerase IIK in yeast cells which also
expressed wt human topoisomerase IIK protein. The Tyr50-
Phe mutant was used as it shows the same resistance to ICRF-
187 as Tyr165Ser in the decatenation assays [11], while
Arg162Gln is drug-sensitive in this assay (Fig. 3). Single ex-
pression of either Tyr50Phe or Tyr165Ser conferred, as ex-
pected, high level drug resistance to ICRF-187 in a 24 h clo-
nogenic assay (Fig. 5, upper panel). However, when co-
expressed with wt, it is obvious that the increase in sensitivity
in wt/Tyr50Phe is much greater than that conferred by wt/
Table 2
Summary of the similarities and di¡erences between wt and the three functional mutations derived from mammalian cell lines selected for bis-
dioxopiperazine resistance
Mutation wt Tyr50Phe Arg162Gln Tyr165Ser
Topo IIK band depl. by ICRF-187 yes no no no
Inhib. of etoposide-induced SSBs yes no no no
Inhib. of etoposide cytotox. by ICRF yes no yes yes
DNA cleavage at high ICRF-187 concentration yes ND no no
Increase in ATP demand wt ND yes yes
ICRF-187 inhibition of kDNA decatenation sensitive resistant sensitive resistant
Dominance/recessiveness wt rec rec dom
Abbreviations: dom, dominant; ND, not done; rec, recessive; SSB, single strand breaks; topo, topoisomerase.
Fig. 3. Catalytic topoisomerase II kDNA decatenation assay using
puri¢ed human wt and Tyr165Ser and Arg162Gln mutant enzyme.
Tyr165Ser enzyme is completely resistant to ICRF-187-mediated in-
hibition of decatenation while Arg162Gln demonstrates wt sensitiv-
ity.
Fig. 4. Full-length cDNA products (4723 nt) of wt NYH and
NYH/187/165 digested with BpmI demonstrating a heterozygous ex-
pression of wt and mutant topoisomerase IIK cDNA in NYH/187/
165 cells. Thus, wt NYH cDNA has one restriction site creating
two bands of 3020 and 1703 nt, while the ACC point mutation at
nt 494 in NYH/187/165 cDNA creates a new restriction site that
cleaves the 1703 nt fragment into 1114 and 589 nt bands.
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Tyr165Ser (Fig. 5, lower panel). As topoisomerase II is a
dimeric enzyme, this indicates that wt/Tyr50Phe heterodimers
are more drug-sensitive than wt/Tyr165Ser heterodimers.
4. Discussion
Bisdioxopiperazines have a dual e¡ect on topoisomerase II,
namely locking its N-terminal clamp and inhibiting its ATP-
ase activity. Olland and Wang [8], using the N-terminal 1^409
aa of yeast topoisomerase II, showed that the bisdioxopiper-
azine ICRF-193 inhibited the ATPase activity of this fragment
suggesting that the drug interacts directly with the paired
N-terminal clamp. There is thus an indication of a bisdioxo-
piperazine pharmacophore in the N-terminal clamp. On the
other hand, it is conceivable that the mutations in and around
the Walker A ATP binding site confer bisdioxopiperazine re-
sistance in an indirect way by shifting the equilibrium of the
enzyme to the early, open clamp form which would obviously
hinder the bisdioxopiperazine to lock the enzyme in its closed
clamp con¢guration. This could be achieved by an increase in
their ATP requirement, which is indeed found in both
Arg162Gln and Tyr165Ser mutant enzymes. However, as
shown in Fig. 2, yeast cells carrying the Arg450Gln mutation
in the Walker B ATP binding site, which also has an increased
ATP requirement, lack resistance to ICRF-187, indicating
that changes in ATP requirement per se are not su⁄cient.
Thus, the question is whether the Walker A ATP binding
site is part of the bisdioxopiperazine pharmacophore. In this
respect, the new Tyr165Ser mutation is of interest for several
reasons. Firstly, it obviously con¢rms and enhances the im-
portance of the Walker A motif in bisdioxopiperazine resis-
tance. It is also the ¢rst mutation to be expressed in a hetero-
zygous fashion which led us to study this phenomenon in
Fig. 5. Clonogenic assay in yeast cells overexpressing either wt,
Tyr50Phe or Tyr165Ser human topoisomerase IIK together with an
empty vector (upper panel) or co-expressed with wt human topoiso-
merase IIK (lower panel). Both Tyr50Phe and Tyr165Ser mutant
proteins display high level resistance towards bisdioxopiperazines
when co-expressed with the empty vector. However, when co-ex-
pressed with wt protein the Tyr50Phe transfected cells become ap-
proximately a log more sensitive to ICRF-187 than wt/Tyr165Ser
cells.
Fig. 6. Comparison of inhibition of puri¢ed human wt and
Tyr165Ser and Tyr50Phe at very high concentrations of ICRF-187
(upper panel) and ICRF-193 (lower panel). Both mutant enzymes
are inhibited to a similar degree indicating that their intrinsic drug
resistance as homodimers is the same.
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more detail. As shown in Fig. 5, the wt/Tyr50Phe transform-
ant is more drug-sensitive than wt/Tyr165Ser. In addition, in
order to exclude the possibility of the Tyr165Ser enzyme in
itself being more drug-resistant, we compared it with puri¢ed
Tyr50Phe at very high concentrations of both ICRF-187 and
its more potent analogue, ICRF-193. As shown in Fig. 6,
there was no di¡erence between the mutants, again suggesting
that the di¡erence in sensitivity in the wt/mutant co-expres-
sion shown in Fig. 5 is due to dominance in the Tyr165Ser
mutant compared to recessiveness in Tyr50Phe. Thus, while
not biochemically proven, the combined results in this paper
indicate that Tyr165Ser protein is dominant while Tyr50Phe
and Arg162Gln are recessive. If so, it is thus interesting that
while the loss of charge in the Arg162Gln mutation and loss
of a hydroxyl group in the Tyr50Phe appear to have to be
present in both dimers to exert their e¡ect on drug sensitivity,
the structurally more radical loss of a benzyl moiety in
Tyr165Ser appears to be su⁄cient to cause resistance by being
in just one of the dimers. As recently shown in a detailed
kinetic study [9], the bisdioxopiperazine ICRF-193 is deduced
to interact with topoisomerase II bound to one ADP with the
other ATP site open, and actually allowing ATP hydrolysis at
this other site. The result of this complex picture is that
ICRF-193 is not a competitive inhibitor of ATP, and that
topoisomerase II bound to drug continues to hydrolyze
ATP at a reduced rate [9]. This indicates that drug binding
requires a strict steric and/or even asymmetric conformation
of the enzyme. Theoretically the mutations, which are all lo-
cated in the area between the Q-phosphates, could interfere
either with this asymmetry, or with a putative drug binding
pocket. Assuming that the drug acts on the asymmetric state
of the enzyme, one would suppose that there is only one bind-
ing site per enzyme dimer. If so, this could account for the
di¡erences found in relation to the localization of the mutants
and of the recessive/dominant role of the mutants as well. A
suggested model for drug binding based on these assumptions
is shown in Fig. 7.
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the enzyme’s catalytic cycle where one ADP is bound while the oth-
er ATP binding site is free, indicating an asymmetric state. The
drug is illustrated by a solid rectangle when drug binding is possi-
ble, and by a transparent one when drug binding is unattainable.
A: Binding of drug to wt enzyme. B,C: Models of recessive muta-
tions illustrating that in order to accomplish complete resistance
both monomers need to be mutated. D,E: Models for dominant
mutations illustrating that one mutated monomer is su⁄cient to
confer complete resistance.
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